Recruiting
Phase 1
Phase 2

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

Sponsor:

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA

Code:

NCT05574010

Conditions

Celiac Disease

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Cohort 1 in Part A

Cohort 2 in Part A

Placebo: Group 1 in Part B and Part C

Group 2 in Part B and Part C

Group 3 in Part B and Part C

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information